Abbott Laboratories (ABT) Liabilities and Shareholders Equity (2009 - 2026)

Abbott Laboratories has disclosed Liabilities and Shareholders Equity across 18 years of filings, most recently posting $110.4 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $110.4 billion, up 35.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $365.3 billion (up 17.76% YoY), and the FY2025 annual result was $86.7 billion, up 6.51% from the prior year.
• Liabilities and Shareholders Equity came in at $110.4 billion for Q1 2026 at Abbott Laboratories, up from $86.7 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $110.4 billion in Q1 2026 to a low of $2.9 billion in Q4 2022.
• The 5-year median for Liabilities and Shareholders Equity is $74.0 billion (2022), against an average of $74.4 billion.
• Across the five-year window, Liabilities and Shareholders Equity sank 60.29% in 2022 and jumped 2439.51% in 2023, its largest moves.
• Abbott Laboratories' Liabilities and Shareholders Equity stood at $2.9 billion in 2022, then surged by 2439.51% to $73.2 billion in 2023, then rose by 11.2% to $81.4 billion in 2024, then climbed by 6.51% to $86.7 billion in 2025, then increased by 27.35% to $110.4 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $110.4 billion (Q1 2026), $86.7 billion (Q4 2025), and $84.2 billion (Q3 2025), per Business Quant data.